Supernus Pharmaceuticals, Inc. has taken a significant step by filing a post-effective amendment to deregister certain securities following its merger with Indivior Pharmaceuticals, Inc. This filing, dated November 2, 2026, indicates a strategic transition for Supernus as it becomes a wholly owned subsidiary of Indivior. The merger could set a precedent for further consolidation in the pharmaceutical preparations industry.

Background

Supernus Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker SUPN. Recent filings indicate that Supernus has been active in the market, with several filings on November 2, 2026, including this deregistration notice.

What the Filing Says

The filing states, "This Post-Effective Amendment... is being filed by Supernus Pharmaceuticals, Inc., a Delaware corporation, to remove and withdraw from registration all securities registered pursuant to the Registration Statements that remain unissued and unsold." This reflects the company's decision to cease being a public reporting company following the merger.

Impact

The deregistration of these securities affects current and potential shareholders, as the common stock of Supernus will be delisted from the Nasdaq Global Market. Employees and stakeholders who were part of the equity incentive plans may also be impacted by the termination of these offerings.

What's Next

The filing does not say what happens next.